<?xml version="1.0" encoding="UTF-8"?>
<rootTag>
<Award>
<AwardTitle>RAPID: Collaborative Research: Enabling the Development of COVID-19 Vaccines, Therapeutics and Diagnostics through Innovations in Measurement Science</AwardTitle>
<AGENCY>NSF</AGENCY>
<AwardEffectiveDate>05/01/2020</AwardEffectiveDate>
<AwardExpirationDate>04/30/2021</AwardExpirationDate>
<AwardTotalIntnAmount>50000.00</AwardTotalIntnAmount>
<AwardAmount>50000</AwardAmount>
<AwardInstrument>
<Value>Standard Grant</Value>
</AwardInstrument>
<Organization>
<Code>07070000</Code>
<Directorate>
<Abbreviation>ENG</Abbreviation>
<LongName>Directorate For Engineering</LongName>
</Directorate>
<Division>
<Abbreviation>IIP</Abbreviation>
<LongName>Div Of Industrial Innovation &amp; Partnersh</LongName>
</Division>
</Organization>
<ProgramOfficer>
<SignBlockName>Prakash Balan</SignBlockName>
<PO_EMAI>pbalan@nsf.gov</PO_EMAI>
<PO_PHON>7032925341</PO_PHON>
</ProgramOfficer>
<AbstractNarration>This broader impacts of this proposed RAPID proposal is to provide critically enabling measurement science tools to government, industry and academic professionals engaged in mitigating the effects of COVID-19 through work from the NSF Industry-University Cooperative Research Center for Bioanalytic Metrology (CBM). Researchers at Indiana University have developed unique instrumentation to determine the composition of very large particles such as viruses, and they will characterize viruses, vaccine candidates, and antibodies bound to viral particles. Making this unique instrumentation generally available to researchers working on COVID-19 vaccines across the national network of government, industry and academic researchers will quickly address the measurement science problems that will inevitably arise during the race to develop a safe and reproducible vaccine. In parallel, the CBM will address challenges of rapid antibody tests that are not quantitative nor highly sensitive, and typical lab-based methods for determining antibody concentrations are long and cumbersome. Researchers at the University of Notre Dame and Purdue University will develop devices to rapidly quantify the amount of COVID-19 antibodies in patient serum. Such analyses are vital for low-cost examination of antibody levels (and hence immunity) over time. The proposed devices will exploit a combination of innovative antibody capture technology developed at Notre Dame, which provides enhanced signals, and Purdue Universityâ€™s expertise in the development of point-of-care diagnostic devices. These measurements will be important for investigating the problem of fading immunity and determining if convalescent plasma from a given patient is appropriate for therapeutic studies.  &lt;br/&gt;&lt;br/&gt;The proposed RAPID research aims to provide fundamental knowledge of the structure of COVID-19 and its elicited antibody response. Analytical and measurement science support of vaccine and biomolecular therapeutic research is notoriously difficult. The molecules in question are often too big and complex for standard characterization methods, and many questions about heterogeneity, stoichiometry and structure cannot easily be answered. Researchers will use advancements in Charge Detection Mass Spectrometry (CDMS) and Ion Mobility Spectrometry (IMS) to study the heterogeneity, stoichiometry, structure and interactions of viral protein assemblies and to provide essential measurements for characterizing newly developed vaccine and therapeutic candidates for COVID-19. The CDMS and IMS tools at the CBM are unique and will allow researchers to directly observe inactivated viruses, 'dummy' viral particles without nucleic acids, bioconjugates containing immunogens on a hapten carrier, oligonucleotides, antibodies complexed to target proteins, and antibodies bound to viral particles. These instruments are starting to revolutionize the analysis of bioconjugations, vaccine development, gene therapies and protein therapeutics. Development of devices for rapidly examining antibody titer will rely on antibody capture in porous membranes that have a long pathlength for sensitive optical detection and a high surface area to volume ratio that enables efficient antibody capture. Device design will exploit expertise in the development of thin strip microfluidic diagnostics. Based on the fluorescence intensity of captured secondary antibodies, these devices will provide a measure of the abundance of different classes of COVID-19 antibodies.&lt;br/&gt;&lt;br/&gt;This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.</AbstractNarration>
<MinAmdLetterDate>05/01/2020</MinAmdLetterDate>
<MaxAmdLetterDate>05/01/2020</MaxAmdLetterDate>
<ARRAAmount/>
<TRAN_TYPE>Grant</TRAN_TYPE>
<CFDA_NUM>47.041</CFDA_NUM>
<NSF_PAR_USE_FLAG>1</NSF_PAR_USE_FLAG>
<FUND_AGCY_CODE>4900</FUND_AGCY_CODE>
<AWDG_AGCY_CODE>4900</AWDG_AGCY_CODE>
<AwardID>2031084</AwardID>
<Investigator>
<FirstName>Jacqueline</FirstName>
<LastName>Linnes</LastName>
<PI_MID_INIT>C</PI_MID_INIT>
<PI_SUFX_NAME/>
<PI_FULL_NAME>Jacqueline C Linnes</PI_FULL_NAME>
<EmailAddress>jlinnes@purdue.edu</EmailAddress>
<PI_PHON>7654961012</PI_PHON>
<NSF_ID>000729849</NSF_ID>
<StartDate>05/01/2020</StartDate>
<EndDate/>
<RoleCode>Principal Investigator</RoleCode>
</Investigator>
<Institution>
<Name>Purdue University</Name>
<CityName>West Lafayette</CityName>
<ZipCode>479072114</ZipCode>
<PhoneNumber>7654941055</PhoneNumber>
<StreetAddress>Young Hall</StreetAddress>
<StreetAddress2><![CDATA[155 S Grant Street]]></StreetAddress2>
<CountryName>United States</CountryName>
<StateName>Indiana</StateName>
<StateCode>IN</StateCode>
<CONGRESSDISTRICT>04</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_ORG>IN04</CONGRESS_DISTRICT_ORG>
<ORG_DUNS_NUM>072051394</ORG_DUNS_NUM>
<ORG_LGL_BUS_NAME>PURDUE UNIVERSITY</ORG_LGL_BUS_NAME>
<ORG_PRNT_DUNS_NUM>072051394</ORG_PRNT_DUNS_NUM>
</Institution>
<Performance_Institution>
<Name><![CDATA[Purdue University]]></Name>
<CityName/>
<StateCode>IN</StateCode>
<ZipCode>479062114</ZipCode>
<StreetAddress/>
<CountryCode>US</CountryCode>
<CountryName>United States</CountryName>
<StateName>Indiana</StateName>
<CountryFlag>1</CountryFlag>
<CONGRESSDISTRICT>04</CONGRESSDISTRICT>
<CONGRESS_DISTRICT_PERF>IN04</CONGRESS_DISTRICT_PERF>
</Performance_Institution>
<ProgramElement>
<Code>1662</Code>
<Text>PFI-Partnrships for Innovation</Text>
</ProgramElement>
<ProgramElement>
<Code>5761</Code>
<Text>IUCRC-Indust-Univ Coop Res Ctr</Text>
</ProgramElement>
<ProgramReference>
<Code>096Z</Code>
<Text>COVID-19 Research</Text>
</ProgramReference>
<ProgramReference>
<Code>7914</Code>
<Text>RAPID</Text>
</ProgramReference>
<Appropriation>
<Code>0120</Code>
<Name>NSF RESEARCH &amp; RELATED ACTIVIT</Name>
<APP_SYMB_ID>040100</APP_SYMB_ID>
</Appropriation>
<FUND_OBLG>2020~50000</FUND_OBLG>
<POR>
<DRECONTENT><![CDATA[<div class="porColContainerWBG"> <div class="porContentCol"><p><span>This collaborative research included unprecedented characterization of virus structures (Indiana University), exploration of the capture and detection of anti-SARS-CoV-2 antibodies in serum and plasma in a rapid colorimetric assay (Purdue University), and development of a 5-min assay for a SARS-CoV-2 antibody (University of Notre Dame).&nbsp; This report describes the research performed at Purdue University. Measurement of antibodies in human serum and plasma is important for monitoring antibody therapies, assessing immune responses to vaccines, and screening donor serum for convalescent serum therapy.&nbsp;</span></p> <p><span>The research focused on developing a new protocol and comparing antibodies used in existing rapid lateral flow immunoassay (LFIA) tests for HIV antigen p24 with new antibodies designed against the SARS-CoV-2 spike receptor binding domain (RBD). The spike RBD is considered the most antigen portion of SARS-CoV-2 and therefore, human antibodies are most likely to be generated against this portion of the virus and have the potential to be detected via LFIA.</span></p> <p><span>We developed a screening protocol for the antibodies using biolayer interferometry, compared four separate HIV p24 antibodies used in LFIAs, and two monoclonal antibodies against the SARS-CoV-2 RBD. Kinetic binding analyses were performed using an OctetRed384 biolayer interferometry system (Sartorius GmbH) to quantify binding of two separate monoclonal antibodies: Leinco Technologies anti-SARS-CoV-2 Spike RBD Clone 2355 (referred to as LN in this report) and Sino Biological SARS-CoV-2 Spike Antibody Chimeric Mab (referred to as SB) against Sino Biological's SARS-CoV-2 Spike His-tagged Recombinant Protein (Catalog Number: 40591-V08H). Antigen and antibody were selected based on previous literature which had shown strong equilibrium binding of these antibodies against the SARS-CoV-2 Spike protein. However, the binding kinetics, particularly rapid binding to the antigen, are critical to rapid lateral flow immunoassays (LFIAs). We performed kinetic studies of antigen-antibody binding as well as sandwich immunoassays to evaluate antibody suitability for LFIA.</span></p> <p><span>The SARS-CoV-2 monoclonal antibodies showed rapid binding (within 5 minutes) and high affinity (no appreciable dissociation within the following 5 minutes) for the RBD, and had binding rates similar to existing HIV p24 antibodies. Therefore, they were deemed appropriate for rapid LFIA detection of SARS-CoV-2 RBD. Initial immunoassays on nitrocellulose employed the immobilized RBD protein for the capture and detection of these anti-SARS-CoV-2 antibodies in a single-step colorimetric assay: SARS-CoV-2 antibodies were bound to gold nanoparticles that successfully aggregated upon antibody binding to the RBD peptide. It is anticipated that host antibody responses would displace these monoclonal antibodies and result in a reduced signal intensity. Future work is needed to further optimize binding and reduce background signal, however, the design could ultimately provide rapid onsite assessment of COVID-19 immunity and vaccine efficacy. Further, leveraging kinetic analyses of antibody binding and selection via biolayer interferometry will allow for targeted design of rapid tests to detect therapeutic antibodies treating diseases ranging from infections to cancer.</span></p><br> <p>            Last Modified: 07/06/2021<br>      Modified by: Jacqueline&nbsp;C&nbsp;Linnes</p> </div> <div class="porSideCol"> <div class="each-gallery"> <div class="galContent" id="gallery0"> <div class="photoCount" id="photoCount0">          Image         </div> <div class="galControls onePhoto" id="controls0"></div> <div class="galSlideshow" id="slideshow0"></div> <div class="galEmbox" id="embox"> <div class="image-title"></div> </div> </div> <div class="galNavigation onePhoto" id="navigation0"> <ul class="thumbs" id="thumbs0"> <li> <a href="/por/images/Reports/POR/2021/2031084/2031084_10667552_1625508402697_Figure1-Schemeofcompetitiveassay--rgov-214x142.jpg" original="/por/images/Reports/POR/2021/2031084/2031084_10667552_1625508402697_Figure1-Schemeofcompetitiveassay--rgov-800width.jpg" title="Figure 1: Scheme of competitive colorimetric assay detecting host antibodies."><img src="/por/images/Reports/POR/2021/2031084/2031084_10667552_1625508402697_Figure1-Schemeofcompetitiveassay--rgov-66x44.jpg" alt="Figure 1: Scheme of competitive colorimetric assay detecting host antibodies."></a> <div class="imageCaptionContainer"> <div class="imageCaption">Figure 1: Scheme of competitive colorimetric assay detecting host antibodies. When few host antibodies are present, detection antibodies bind to the antigen resulting in color development. When many host antibodies are present the detection antibodies are displaced and no color development occurs.</div> <div class="imageCredit">Jacqueline C. Linnes</div> <div class="imagePermisssions">Creative Commons</div> <div class="imageSubmitted">Jacqueline&nbsp;C&nbsp;Linnes</div> <div class="imageTitle">Figure 1: Scheme of competitive colorimetric assay detecting host antibodies.</div> </div> </li> </ul> </div> </div> </div> </div>]]></DRECONTENT>
<POR_COPY_TXT><![CDATA[ This collaborative research included unprecedented characterization of virus structures (Indiana University), exploration of the capture and detection of anti-SARS-CoV-2 antibodies in serum and plasma in a rapid colorimetric assay (Purdue University), and development of a 5-min assay for a SARS-CoV-2 antibody (University of Notre Dame).  This report describes the research performed at Purdue University. Measurement of antibodies in human serum and plasma is important for monitoring antibody therapies, assessing immune responses to vaccines, and screening donor serum for convalescent serum therapy.   The research focused on developing a new protocol and comparing antibodies used in existing rapid lateral flow immunoassay (LFIA) tests for HIV antigen p24 with new antibodies designed against the SARS-CoV-2 spike receptor binding domain (RBD). The spike RBD is considered the most antigen portion of SARS-CoV-2 and therefore, human antibodies are most likely to be generated against this portion of the virus and have the potential to be detected via LFIA.  We developed a screening protocol for the antibodies using biolayer interferometry, compared four separate HIV p24 antibodies used in LFIAs, and two monoclonal antibodies against the SARS-CoV-2 RBD. Kinetic binding analyses were performed using an OctetRed384 biolayer interferometry system (Sartorius GmbH) to quantify binding of two separate monoclonal antibodies: Leinco Technologies anti-SARS-CoV-2 Spike RBD Clone 2355 (referred to as LN in this report) and Sino Biological SARS-CoV-2 Spike Antibody Chimeric Mab (referred to as SB) against Sino Biological's SARS-CoV-2 Spike His-tagged Recombinant Protein (Catalog Number: 40591-V08H). Antigen and antibody were selected based on previous literature which had shown strong equilibrium binding of these antibodies against the SARS-CoV-2 Spike protein. However, the binding kinetics, particularly rapid binding to the antigen, are critical to rapid lateral flow immunoassays (LFIAs). We performed kinetic studies of antigen-antibody binding as well as sandwich immunoassays to evaluate antibody suitability for LFIA.  The SARS-CoV-2 monoclonal antibodies showed rapid binding (within 5 minutes) and high affinity (no appreciable dissociation within the following 5 minutes) for the RBD, and had binding rates similar to existing HIV p24 antibodies. Therefore, they were deemed appropriate for rapid LFIA detection of SARS-CoV-2 RBD. Initial immunoassays on nitrocellulose employed the immobilized RBD protein for the capture and detection of these anti-SARS-CoV-2 antibodies in a single-step colorimetric assay: SARS-CoV-2 antibodies were bound to gold nanoparticles that successfully aggregated upon antibody binding to the RBD peptide. It is anticipated that host antibody responses would displace these monoclonal antibodies and result in a reduced signal intensity. Future work is needed to further optimize binding and reduce background signal, however, the design could ultimately provide rapid onsite assessment of COVID-19 immunity and vaccine efficacy. Further, leveraging kinetic analyses of antibody binding and selection via biolayer interferometry will allow for targeted design of rapid tests to detect therapeutic antibodies treating diseases ranging from infections to cancer.       Last Modified: 07/06/2021       Submitted by: Jacqueline C Linnes]]></POR_COPY_TXT>
</POR>
</Award>
</rootTag>
